Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Average Annual Pay for PMDA Staffers at 7.99 Million Yen in FY2024
July 1, 2025
- LDP’s Furukawa Vows Policy Support for Domestic Innovation in New Modalities
June 30, 2025
- MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
- Japan Hands Out Orphan Tags to Ultragenyx’s Setrusumab and Lots More
June 30, 2025
- Japan Launches Public-Private Council to Create Innovation Ecosystem
June 27, 2025
- DPP’s Tamura Renews Call to Scrap Off-Year Drug Price Cuts, Urges Protection of On-Patent Prices
June 26, 2025
- Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
June 26, 2025
- Chuikyo OKs Drug Price Survey Plan for FY2026 Revision
June 26, 2025
- Study Group Urges Japan to Accelerate Genomic Medicine Rollout
June 26, 2025
- MHLW Orders Label Revisions for Desmopressin, Thiamazole
June 25, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
- JPWA Poll Finds Progress in Unit Price-Based Negotiations, but Frequent and Lengthy Bargaining Persists
June 25, 2025
- Japan Sets June 26 for First Meeting of Public-Private Council for Biopharmaceutical Innovation
June 24, 2025
- MHLW Survey Flags Low Rate of Unit Price-Based Deals When Agents Involved
June 24, 2025
- LDP Official: Higher Tax Revenue Could Fund Expansion of Minimum NHI Prices, Re-Pricing for Unprofitable Products
June 20, 2025
- Japan Puts a Hold on Coverage Discussions for Elevidys over Safety Concerns
June 19, 2025
- Japan to Delete 16 Drugs from NHI Price List under New Streamlined Process
June 19, 2025
- LDP Lawmakers Seek Early Male NIP Coverage for HPV Jabs
June 18, 2025
- Generic Fund Is to Support Costs Tied to Product Consolidation: Official
June 18, 2025
- Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…